ThromboGenics has entered into an agreement with Alcon, a division of Novartis, for the commercialisation of ocriplasmin in all markets outside the US. As a result of this deal, ThromboGenics will concentrate on marketing the product in the US, where it plans to build a commercial and medical organisation to support the product's anticipated launch within the next 12 months.
Under the terms of the agreement, ThromboGenics will receive an upfront payment of EUR 75 million and up to EUR 90 million in further potential near-term milestone payments. Additional milestones bring the potential total of upfronts and milestones to EUR 375 million. In addition, ThromboGenics will receive royalties on net sales of ocriplasmin. ThromboGenics will have a strategic and focused operational role in the commercialisation of ocriplasmin in the five largest European markets, enabling it to build the foundation for an expanding ophthalmology business.
In addition to the commercial introduction of ocriplasmin in markets outside the US, the agreement specifies that Alcon and ThromboGenics will work together, and share the costs, to further develop new clinical applications of the product in their respective territories.